Private Companies
Delix Therapeutics to start clinical trial on novel psychoplastogen drug
DLX-001 is a non-hallucinogenic compound intended to treat various mental health conditions
The post Delix Therapeutics to start clinical trial on novel…
Delix Therapeutics, a neuroscience company based in Boston Massachusetts, has received approval for a Phase I clinical trial examining its novel non-hallucinogenic psychoplastogen drug DLX-001.
The company announced the regulatory approval for the study on Tuesday and plans to enroll 100 healthy volunteers in the trial at the Center for Human Drug Research in the Netherlands. The company has not specified when the trial will begin.
DLX-001 is the first approved psychoplastogen from Delix’s platform, based on the work of the company’s co-founder David E. Olson.
His research at the University of California, Davis, led to the discovery of novel psychoplastogens with significant therapeutic potential in preclinical models, without the hallucinogenic side effects of earlier generations.
UC Davis established an Institute for Psychedelics and Neurotherapeutics in February with the intention of advancing safe and effective treatments for diseases such as depression, Parkinson’s, PTSD, substance use disorders and Alzheimer’s.
Diagram of how psychoplastogens work. Photo via Delix Therapeutics
Read more: Delix gets recognized as leading start-up by Nature Biotechnology
Read more: PhD graduates from UBC launch new company in Nevada
DLX-001 is a compound from Delix’s extensive library of active compounds that are said to promote enduring neuroplasticity, with efficacy comparable to or better than natural psychedelic compounds. Unlike the natural compounds, DLX-001 is not psychoactive, even at high doses, which Delix says is evidenced by preclinical models.
“With the continued rise of mental health diagnoses across the globe and a significant lack of innovative treatment options available for those suffering, we are excited about the potential of psychoplastogens — especially scaleable non-hallucinogenic compounds — to treat a variety of conditions as safe and effective take-at-home medicines,” said Delix’s CEO Mark Rus, adding that this first in-human trial is the result of years of preclinical studies and results.
Delix was recognized as a leading start-up company in September last year by the renowned scientific journal Nature Biotechnology.
The company has established a substantial private investor base comprised of firms such as RA Capital, Artis Ventures and Dolby Family Ventures.
rowan@mugglehead.com
The post Delix Therapeutics to start clinical trial on novel psychoplastogen drug appeared first on Mugglehead Magazine.
psychoactive psychedelics psychedelic capital delix therapeutics delix research
-
Psilocybin6 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics6 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics6 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation6 days agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics6 days agoOptimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
-
Law & Regulation6 days ago
Adastra reports record sales in 2023, but remains in the red
